Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q2 EPS of $0.87, $1.28 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $80 million versus the consensus estimate of $1.78 million.

For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.